Tarsus Pharmaceuticals, Inc. TARS

Rank #2438 · Nasdaq · $3.2B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

18.5

P/E

-23.7

P/B

16.69

ROE

-70.4%

Op. Margin

-820.5%

Debt Ratio

79%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -23.7x, P/B 16.69x. Ranks in the top 82% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -70.4%. Ranks in the top 94% of the universe.

Safety ★★★☆☆

Good

Debt ratio 79%. Ranks in the top 33% of the universe.

Growth ★☆☆☆☆

Poor

Revenue decline of 32.4% year over year. Ranks in the top 95% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	–	$-0.0B	$-0.0B	$-0.0B	–	-2089
2021	$0.0B	$-0.0B	$-0.0B	$-0.0B	–	-100
2022	$0.1B	$-0.0B	$-0.0B	$0.2B	-21.3	7
2023	$0.0B	$-0.1B	$-0.1B	$0.2B	-242.9	21
2024	$0.0B	$-0.1B	$-0.1B	$0.2B	-242.9	41
2025	$0.0B	$-0.1B	$-0.1B	$0.2B	-820.5	79